Erratum: The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013(J Rheumatol (2016) 43(1618)10.3899/jrheum.150997);The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013

Journal of Rheumatology

Volumn 43, Issue 9, 2016, Pages 1755-1762

  Janow, Ginger ^a   Schanberg, Laura E ^b   Setoguchi, Soko ^c   Hasselblad, Victor ^b   Mellins, Elizabeth D ^c   Schneider, Rayfel ^d,e   Kimura, Yukiko ^a   Abramson, L ^f   Anderson, E ^f   Andrew, M ^f   Battle, N ^f   Benham, H ^f   Beukelman, T ^f   Birmingham, J D ^f   Blier, P ^f   Cabrera, A ^f   Canter, D ^f   Carlton, D ^f   Caruso, B ^f   Ceracchio, L ^f   Chalom, E ^f   Chang, J ^f   Charpentier, P ^f   Clark, K ^f   Dean, J ^f   Debolt, C ^f   Dedeoglu, F ^f   Ferguson, P J ^f   Fox, M ^f   Francis, K ^f   Gervasini, M ^f   Gorton, G ^f   Gottlieb, B ^f   Graham, T ^f   Griffin, T ^f   Grosbein, H ^f   Guppy, S ^f   Haftel, H ^f   Helfrich, D ^f   Higgins, G ^f   Hillard, A ^f   Hollister, J R ^f   Hsu, J ^f   Hudgins, A ^f   Hung, C ^f   Huttenlocher, A ^f   Ibarra, M ^f   Ilowite, N ^f   Imlay, A ^f   Imundo, L ^f   Jaqith, J ^f   Jung, L ^f   Kapedani, A ^f   Kingsbury, D ^f   Klein, K ^f   Klein Gitelman, M ^f   Kunkel, A ^f   Layburn, S ^f   Lindsley, C ^f   Macgregor Hannah, M ^f   Malloy, M ^f   Mawhorter, C ^f   McCurdy, D ^f   Mims, K ^f   Mistry, N ^f   Moorthy, L N ^f   Morus, D ^f   Muscal, E ^f   Natter, M ^f   Olson, J ^f   O'Neil, K ^f   Onel, K ^f   Orlando, M ^f   Phillips, M ^f   Ponder, L ^f   Prahalad, S ^f   Punaro, M ^f   Puplava, D ^f   Quinn, S ^f   Quintero, A ^f   Rabinovich, C ^f   Reed, A ^f   Reed, C ^f   Ringold, S ^f   Riordan, M ^f   Roberson, S ^f   Robinson, A ^f   Rossette, J ^f   Russo, D ^f   Ruth, N ^f   Schikler, K ^f   Sestak, A ^f   Shaham, B ^f   Sherman, Y ^f   Simmons, M ^f   Singer, N ^f   Smith, C N ^f   Stapp, H ^f   Syed, R ^f   Thomas, E ^f   Toib, D ^f   Torok, K ^f   Trejo, D ^f   Tress, J ^f   Upton, W ^f   Vehe, R ^f   Von Scheven, E ^f   Walters, L ^f   Weiss, J E ^f   Weiss, P F ^f   Welnick, N ^f   White, A ^f   Woo, J ^f   Wootton, J ^f   Yalcindag, A ^f   Zapp, C ^f   Zemel, L ^f   more..

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f NONE

Author keywords

Epidemiology; Systemic juvenile idiopathic arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT;

AFRICAN AMERICAN; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG USE; FEMALE; FEVER; FUNCTIONAL STATUS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PAIN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SCHOOL CHILD; SCORING SYSTEM; AGE; COHORT ANALYSIS; ONSET AGE; PHENOTYPE; PRESCHOOL CHILD; REGISTER; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SYMPTOM ASSESSMENT;

AGE FACTORS; AGE OF ONSET; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PHENOTYPE; REGISTRIES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SYMPTOM ASSESSMENT;

EID: 84984950327     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150997.C1     Document Type: Erratum

References (45)

1. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98.
2. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
4. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;54:1595-601.
5. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
6. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al; PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
7. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al; Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67.
8. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first line use of recombinant IL-1RA treatment in steroid naive systemic juvenile idiopathic arthritis: results of a prospective cohort study [abstract]. Arthritis Rheum 2013;65 Suppl 10:S759.
9. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
10. Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, et al. The randomized placebo phase study of rilonacept in the treatment of systemic juvenile idiopathic arthritis (RAPPORT). Arthritis Rheumatol 2014;66:2570-9.
11. Natter MD, Quan J, Ortiz DM, Bousvaros A, Ilowite NT, Inman CJ, et al. An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc 2013;20:172-9.
12. Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al; CARRA Registry Investigators. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012;39:1867-74.
13. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013;72:1806-12.
14. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012;64:1001-10.
15. Berntson L, Andersson Gäre B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al; Nordic Study Group. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30:2275-82.
16. Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377-81.
17. Moe N, Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol 1998;16:99-101.
18. Gäre BA, Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 1992;90:950-8.
19. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn 1997;39:245-9.
20. Aoki C, Inaba Y, Choe H, Kaneko U, Hara R, Miyamae T, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol 2014;41:1171-7.
21. Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol 2013;40:329-34.
22. Sandborg C, Holmes TH, Lee T, Biederman K, Bloch DA, Emery H, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol 2006; 33:2322-9.
23. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43:2402-9.
24. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6.
25. Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol 2014;66:1405-13.
26. Kimura Y, Beukelman T, Morgan-DeWitt E, Mieszkalski K, Graham T, Ibarra M, et al. Results from the Childhood Arthritis and Rheumatology Research Alliance systemic JIA Consensus Treatment Plans pilot study [abstract]. Arthritis Rheumatol 2015;67 Suppl 10:959.
27. Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis 2015; 74:1379-86.
28. Kobayashi T, Tanaka S, Maeda M, Okubo H, Matsuyama T, Watanabe N. A study of prognosis in 52 cases with juvenile rheumatoid arthritis. Acta Paediatr Jpn 1993;35:439-46.
29. David J, Cooper C, Hickey L, Lloyd J, Doré C, McCullough C, et al. The functional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br J Rheumatol 1994;33:876-81.
30. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
31. Hanson V, Kornreich H, Bernstein B, King KK, Singsen B. Prognosis of juvenile rheumatoid arthritis. Arthritis Rheum 1977;20 Suppl 2:279-84.
32. Prieur AM, Bremard-Oury C, Griscelli C, Mozziconacci P. [Prognosis of the systemic forms of juvenile chronic arthritis. Apropos of 100 cases]. [Article in French] Arch Fr Pediatr 1984;41:91-7.
33. Hafner R, Truckenbrodt H. [Course and prognosis of systemic juvenile chronic arthritis-retrospective study of 187 patients]. [Article in German] Klin Padiatr 1986;198:401-7.
34. Stoeber E. Prognosis in juvenile chronic arthritis. Follow-up of 433 chronic rheumatic children. Eur J Pediatr 1981;135:225-8.
35. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306:2340-7.
36. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36:1078-82.
37. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
38. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
39. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 2013;65:1551-63.
40. Ringold S, Beukelman T, Nigrovic PA, Kimura Y; CARRA Registry Site Principal Investigators. Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013;40:936-42.
41. Ling XB, Macaubas C, Alexander HC, Wen Q, Chen E, Peng S, et al. Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis. BMC Medicine 2012;10:125.
42. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802.
43. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 2011;38:180-1.
44. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008;35:343-8.
45. Beukelman T, Berntson L, Duffy CM, Guzman J, Kimura Y, Klotsche J, et al. The initial treatment of systemic juvenile idiopathic arthritis: an international collaboration among 7 registries. Ann Rheum Dis 2015;74 Supp l2:392-3.